tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'Diabetes'

Nuvilex’s Acquisition of Diabetes Rights Should Put the Company on Everyone’s Radar

Nuvilex’s Acquisition of Diabetes Rights Should Put the Company on Everyone’s Radar

Written by ι Stock Market Media Group Staff — November 19, 2013

Nuvilex, Inc. (OTCQB: NVLX) recently acquired the exclusive worldwide rights to a proprietary cellulose-based live-cell encapsulation technology for developing treatments for all types of cancer, most notably pancreatic cancer.  This acquisition should put the company and cell encapsulation-based therapies on the map if its future Phase 3 clinical trials in patients with advanced, inoperable pancreatic cancer produce similar data to that seen in two separate early-phase trials in this disease. 

But, ...

Read More →
0

New Report Shows Plandaí Biotechnology’s Diabetes Research More Important Than Ever

New Report Shows Plandaí Biotechnology’s Diabetes Research More Important Than Ever

Written by ι Stock Market Media Group Staff — November 19, 2013

Late last week the International Diabetes Federation (IDF) released a report filled with some staggering statistics in the fight against diabetes.  Plandaí Biotechnology, Inc. (OTCQB: PLPL) feels it is producing products that can make a difference in the fight against the disease, and in light of these new numbers from the IDF, those products will be more welcomed than ever. 

The company’s Phytofare™ Catechin Complex is one of the candidates that Plandaí ...

Read More →
0

Investors Confidently Back Nuvilex’s Acquisition of Diabetes Technology

Investors Confidently Back Nuvilex’s Acquisition of Diabetes Technology

Written by ι Stock Market Media Group Staff — November 12, 2013

Nuvilex, Inc. (OTCQB: NVLX) announced last week that it has acquired the exclusive worldwide rights to a cellulose-based live-cell encapsulation technology for the development of treatments for diabetes.  In order to pull off the acquisition, Nuvilex had to convince investors to part with $1.5 million dollars in cash.  One wouldn’t think this a hard sell given the acquisition could lead to a multi-billion dollar treatment for the company.  And, you’d ...

Read More →
0

Nuvilex, Inc. COO Interview with Dr. Gerald Crabtree

Nuvilex, Inc. COO Interview with Dr. Gerald Crabtree

Nuvilex Inc.’s, (OTCQB: NVLX) Chief Operating Officer, Dr. Gerald Crabtree sat down for an interview with Stock Market Media Group, a research and content development investor relations firm.  In the interview, Dr. Crabtree covered a number of topics including the Nuvilex’s restructuring, its recent acquisition of a live-cell encapsulation-based technology, the company’s future pancreatic cancer clinical trials and the on-going relationship with SG Austria.   

The interview can be heard at www.stockmarketmediagroup.com/media.

As part of Stock Market Media Group’s CEO interview ...

Read More →
0

Plandai Biotechnology, Inc. Involved in Numerous Clinical Trials as Company Prepares Products for Market

Plandai Biotechnology, Inc. Involved in Numerous Clinical Trials as Company Prepares Products for Market

Written by ι Stock Market Media Group Staff — October 3, 2013

Plandaí Biotechnology, Inc. (OTCQB: PLPL) has several clinical trials already underway, and a host of others scheduled to commence in the company months as the company feverishly prepares products for market in its transition from solely a research and development firm to a biotech with products in the marketplace.  Plandaí has stated its goal is to have most of the trials it has commissioned completed by the end of March 2014 ...

Read More →
0

Buy Rating and New Report Issued for Plandai Biotechnology, Inc.

Buy Rating and New Report Issued for Plandai Biotechnology, Inc.

September 23, 2013

Stock Market Media Group, a research and content development investor relations firm, has released its 3rd Quarter report and issued a Speculative Buy Rating on Plandaí Biotechnology, Inc. (OTCQB: PLPL).  The report: Plandaí Biotechnology, Inc. – From R&D to Market, is the first in a series of reports that will follow Plandaí as it transitions from a biotech solely engaged in research and development to a company launching products into the marketplace.

Read the Plandaí Report at www.stockmarketmediagroup.com/reports.

In ...

Read More →
0
Page 5 of 7 «...34567
ContactUs.com